For path to market, we create a high-level map of the required discovery and development steps required for the lead indication.

For each major step we estimate the duration and cost.


Key program risks or challenges are also described.


Benchmark analysis of drugs previously developed for an indication can yield information on the possible wording of the approved indication, the nature and number of trials required, the patient numbers needed to treat, the primary and secondary endpoints, and the duration of late stage trials.

Path To Market